| | TEL AVIV, Israel, Oct. 26, 2023 /PRNewswire/ -ChemomAb Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will present at major U.S. scientific conferences in November, including an oral presentation on primary sclerosing cholangitis and a poster at the AASLD The Liver Meeting® 2023, as well as a poster presentation on the role of Chemomab’s CCL24 target in manifestations of systemic sclerosis at the American College of Rheumatology Convergence 2023. Further details of the presentations will be released in November. AASLD The Liver Meeting® 2023, Boston, MA, Nov. 10-14, 2023 | Date: | Nov. 13, 2023 | | Time: | 4:30pm ET | | Format: | Oral presentation: Serum proteomics reveals unique association of CCL24 with disease-related pathways and signatures in primary sclerosing cholangitis | | Presenter: | Ilan Vaknin, PhD, Vice President of R&D, Chemomab Therapeutics, Ltd. | | Authors: | Tom Snir, Raanan Greenman, Revital Aricha, John Lawler, Francesca Saffioti, Douglas Thorburn, Massimo Pinzani, Adi Mor, Ilan Vaknin | | Session: | Room 312 - Breaking the Chains of Cholestatic Liver Injury: Advancements and Promising Treatment Strategies | | Information: | The Liver Meeting | AASLD | AASLD The Liver Meeting® 2023, Boston, MA, Nov. 10-14, 2023 | Date: | Nov. 11, 2023 | | Time: | 1:00-2:00 pm ET | | Format: | Poster presentation: CM-101, a CCL24 neutralizing antibody, showed improvements in inflammatory, fibrotic, and metabolic pathways in patients with NASH: Proteomics analysis of a Phase 2a study | | Presenter: | Matt Frankel, MD, Chief Medical Officer & Vice President of Drug Development, Chemomab Therapeutics | | Authors: | Revital Aricha, Tom Snir, Ilan Vaknin, John Lawler, Adi Mor, Matt Frankel | | Session: | Poster session Hall C – 2nd level | | Information: | The Liver Meeting | AASLD | American College of Rheumatology Convergence 2023 – San Diego, CA, Nov.10-15, 2023 | Date: | Nov. 14, 2023 | | Time: | 9:00-11:00 am PT | | Format: | Poster presentation: The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients | | Presenter: | Ilan Vaknin, PhD, Vice President of R&D, Chemomab Therapeutics | | Authors: | Itzchak Amoyal, Tzipi Hornik-Lurie, Tali Zitman-Gal, Hilit Levy, Ilan Vaknin Liat Drucker, Ishai Heusler, Yair Levy, Shelly Tartakover Matalo | | Session: | Poster Session C, Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science | | Information: | rheumatology.org/annual-meeting | About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from three clinical trials of CM-101 in patients, including a Phase 1b trial in NAFLD patients, a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. The CM-101 program for the treatment of systemic sclerosis is Phase 2-ready and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with topline data expected in the second half of 2024. For more information about Chemomab, visit chemomab.com. Contacts: Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com IR@chemomab.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-upcoming-scientific-conferences-301968462.html
SOURCE Chemomab Therapeutics, Ltd. | |
